Receptor-targeted nanocarriers for therapeutic delivery to cancer

References

• Abu Lila AS, Ishida T, Kiwada H. 2009. Recent advances in tumor vasculature targeting using liposomal drug delivery systems. Expert Opin Drug Deliv 6:1297–1309.
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, Farokhzad OC. 2008. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505–515.
   PubMed Web of Science ®Google Scholar
• Aliabadi HM, Lavasanifar A. 2006. Polymeric micelles for drug delivery. Expert Opin Drug Deliv 3:139–162.
   PubMedGoogle Scholar
• Allen TM. 2002. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2:750–763.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. 2004. Drug delivery systems: Entering the mainstream. Science 303:1818–1822.
   PubMed Web of Science ®Google Scholar
• Arap W, Pasqualini R, Ruoslahti E. 1998. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377–380.
   PubMed Web of Science ®Google Scholar
• Balestrieri ML, Napoli C. 2007. Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. Eur J Cancer 43:1242–1250.
   PubMed Web of Science ®Google Scholar
• Beuttler J, Rothdiener M, Muller D, Frejd FY, Kontermann RE. 2009. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjug Chem 20:1201–1208.
   PubMed Web of Science ®Google Scholar
• Bhirde AA, Patel V, Gavard J, Zhang G, Sousa AA, Masedunskas A, Leapman RD, Weigert R, Gutkind JS, Rusling JF. 2009. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 3:307–316.
   PubMed Web of Science ®Google Scholar
• Boddapati SV, D'Souza GG, Erdogan S, Torchilin VP, Weissig V. 2008. Organelle-targeted nanocarriers: Specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett 8:2559–2563.
   PubMed Web of Science ®Google Scholar
• Bonacucina G, Cespi M, Misici-Falzi M, Palmieri GF. 2009. Colloidal soft matter as drug delivery system. J Pharm Sci 98:1–42.
   PubMed Web of Science ®Google Scholar
• Brooks H, Lebleu B, Vives E. 2005. Tat peptide-mediated cellular delivery: Back to basics. Adv Drug Deliv Rev 57:559–577.
   PubMed Web of Science ®Google Scholar
• Caliceti P, Veronese FM. 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55:1261–1277.
   PubMed Web of Science ®Google Scholar
• Carter P. 2001. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118–129.
   PubMed Web of Science ®Google Scholar
• Chang DK, Lin CT, Wu, CH, Wu HC. 2009. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One 4:e4171.
   PubMed Web of Science ®Google Scholar
• Chen J, Corbin IR, Li H, Cao W, Glickson JD, Zheng G. 2007. Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J Am Chem Soc 129:5798–5799.
   PubMed Web of Science ®Google Scholar
• Clynes R, Towers T, Presta L, Ravetch J. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443–446.
   PubMed Web of Science ®Google Scholar
• Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, Revets H. 2004. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64:2853–2857.
   PubMed Web of Science ®Google Scholar
• D'Souza GG, Rammohan R, Cheng SM, Torchilin VP, Weissig V. 2003. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release 92:189–197.
   PubMed Web of Science ®Google Scholar
• Daniels TR, Delgado T, Helguera G, Penichet ML. 2006. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121:159–176.
   PubMed Web of Science ®Google Scholar
• Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson M. 2004. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 90:2085–2091.
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. 2008. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–782.
   PubMed Web of Science ®Google Scholar
• De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D'Alessio G. 2002. A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 8:1710–1719.
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. 2010. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 10:9–22.
   PubMed Web of Science ®Google Scholar
• Di Nenedetto M, Starzec A, Vassy R, Perret GY, Crepin M. 2008. Distinct heparin binding sites on VEGF165 and its receptors revealed by their interaction with a non sulfated glycoaminoglycan (NaPaC). Biochim Biophys Acta 1780:723–732.
   PubMedGoogle Scholar
• Dilnawaz F, Singh A, Mohanty C, Sahoo SK. 2010. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31:3694–3706.
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Cottrell W, Spirovski B, Hopkins S. 2009. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. J Oncol Pharm Pract 15:67–78.
   PubMedGoogle Scholar
• Duncan R. 2003. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2:347–360.
   PubMed Web of Science ®Google Scholar
• Duncan R. 2006. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6:688–701.
   PubMed Web of Science ®Google Scholar
• Duncan R. 2009. Development of HPMA copolymer-anticancer conjugates: Clinical experience and lessons learnt. Adv Drug Deliv Rev 61(13):1131–1148.
   PubMed Web of Science ®Google Scholar
• Duncan R, Izzo L. 2005. Dendrimer biocompatibility and toxicity. Advanced Drug Delivery Reviews 57:2215–2237.
   PubMed Web of Science ®Google Scholar
• El Bayoumi TA, Torchilin VP. 2009. Tumor-targeted nanomedicines: Enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 15:1973–1980.
   PubMedGoogle Scholar
• Fang X, Tan W. 2010. Aptamers generated from cell-SELEX for molecular medicine: A chemical biology approach. Acc Chem Res 43:48–57.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. 2006. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103:6315–6320.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. 2009. Impact of nanotechnology on drug delivery. Acs Nano 3:16–20.
   PubMed Web of Science ®Google Scholar
• Futaki S, Masui Y, Nakase I, Sugiura Y, Nakamura T, Kogure K, Harashima H. 2005. Unique features of a pH-sensitive fusogenic peptide that improves the transfection efficiency of cationic liposomes. J Gene Med 7:1450–1458.
   PubMed Web of Science ®Google Scholar
• Ganta S, Devalapally H, Shahiwala A, Amiji M. 2008. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 126:187–204.
   PubMed Web of Science ®Google Scholar
• Garanger E, Boturyn D, Coll JL, Favrot MC, Dumy P. 2006. Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands. Org Biomol Chem 4:1958–1965.
   PubMedGoogle Scholar
• Gindy ME, Prud'homme RK. 2009. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv 6:865–878.
   PubMed Web of Science ®Google Scholar
• Gosk S, Vermehren C, Storm G, Moos T. 2004. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J Cereb Blood Flow Metab 24:1193–1204.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48–58.
   PubMed Web of Science ®Google Scholar
• Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, Langer RS, Farokhzad OC. 2007. Targeted nanoparticles for cancer therapy. Nano Today 2:14–21.
   Web of Science ®Google Scholar
• Gullotti E, Yeo Y. 2009. Extracellularly activated nanocarriers: A new paradigm of tumor targeted drug delivery. Mol Pharm 6:1041–1051.
   PubMed Web of Science ®Google Scholar
• Hawkins MJ, Soon-Shiong P, Desai N. 2008. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60:876–885.
   PubMed Web of Science ®Google Scholar
• Heath JR, Davis ME. 2008. Nanotechnology and cancer. Annu Rev Med 59:251–265.
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. 1998. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607–4612.
   PubMed Web of Science ®Google Scholar
• Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, Tan W. 2009. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 10:862–868.
   PubMed Web of Science ®Google Scholar
• Jagur-Grodzinski J. 2009. Polymers for targeted and/or sustained drug delivery. Polymers for Adv Technol 20:595–606.
   Web of Science ®Google Scholar
• Jain RK. 1999. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1:241–263.
   PubMed Web of Science ®Google Scholar
• Kakudo T, Chaki S, Futaki S, Nakase I, Akaji K, Kawakami T, Maruyama K, Kamiya H, Harashima H. 2004. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: An artificial viral-like delivery system. Biochemistry 43:5618–5628.
   PubMed Web of Science ®Google Scholar
• Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D. 1997. Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro. Biochemistry 36:66–75.
   PubMed Web of Science ®Google Scholar
• Kluza E, van der Schaft DW, Hautvast PA, Mulder WJ, Mayo KH, Griffioen AW, Strijkers GJ, Nicolay K. 2010. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett 10:52–58.
   PubMed Web of Science ®Google Scholar
• Krishna AD, Mandraju RK, Kishore G, Kondapi AK. 2009. An efficient targeted drug delivery through apotransferrin loaded nanoparticles. PLoS One 4:e7240.
   PubMed Web of Science ®Google Scholar
• Laginha K, Mumbengegwi D, Allen T. 2005. Liposomes targeted via two different antibodies: Assay, B-cell binding and cytotoxicity. Biochim Biophys Acta 1711:25–32.
   PubMed Web of Science ®Google Scholar
• Laginha KM, Moase EH, Yu N, Huang A, Alien TM. 2008. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer. J Drug Target 16:605–610.
   PubMed Web of Science ®Google Scholar
• Lam R, Ho D. 2009. Nanodiamonds as vehicles for systemic and localized drug delivery. Expert Opin Drug Deliv 6:883–895.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. 2008. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 112:5180–5189.
   PubMed Web of Science ®Google Scholar
• Leuschner C, Kumar CS, Hansel W, Soboyejo W, Zhou J, Hormes J. 2006. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat 99:163–176.
   PubMed Web of Science ®Google Scholar
• Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. 2008. Nanotechnology and aptamers: Applications in drug delivery. Trends Biotechnol 26:442–449.
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. 2008. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5:496–504.
   PubMed Web of Science ®Google Scholar
• Loomis K, Smith B, Feng Y, Garg H, Yavlovich A, Campbell-Massa R, Dimitrov DS, Blumenthal R, Xiao X, Puri A. 2010. Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. Exp Mol Pathol 88:238–249.
   PubMed Web of Science ®Google Scholar
• Lopes de Menezes DE, Pilarski LM, Allen TM. 1998. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58:3320–3330.
   PubMed Web of Science ®Google Scholar
• Low PS, Henne WA, Doorneweerd DD. 2008. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41:120–129.
   PubMed Web of Science ®Google Scholar
• MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K, Brahmbhatt VN, Phillips L, Pattison ST, Petti C, Stillman B, Graham RM, Brahmbhatt H. 2009. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 27:643–651.
   PubMed Web of Science ®Google Scholar
• MacDiarmid JA, Madrid-Weiss J, Amaro-Mugridge NB, Phillips L, Brahmbhatt H. 2007a. Bacterially-derived nanocells for tumor-targeted delivery of chemotherapeutics and cell cycle inhibitors. Cell Cycle 6:2099–2105.
   PubMed Web of Science ®Google Scholar
• MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RP, Haasdyk JE, Dickson KA, Brahmbhatt VN, Pattison ST, James AC, Al Bakri G, Straw RC, Stillman B, Graham RM, Brahmbhatt H. 2007b. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 11:431–445.
   PubMed Web of Science ®Google Scholar
• Matsui M, Shimizu Y, Kodera Y, Kondo E, Ikehara Y, Nakanishi H. 2010. Targeted delivery of oligomannose-coated liposome to the omental micrometastasis by peritoneal macrophages from patients with gastric cancer. Cancer Sci 101:1670–1677.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N. 2004. Phase I clinical trial and pharmacokinetic evaluations of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91:1775–1781.
   PubMed Web of Science ®Google Scholar
• McCarthy JR, Weissleder R. 2008. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 60:1241–1251.
   PubMed Web of Science ®Google Scholar
• Miele E, Spinelli GP, Tomao F, Tomao S. 2009. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed 4:99–105.
   PubMed Web of Science ®Google Scholar
• Mishra B, Patel BB, Tiwari S. 2010. Colloidal nanocarriers: A review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 6:9–24.
   PubMed Web of Science ®Google Scholar
• Misra R, Sahoo SK. 2010. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci 39:152–163.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Weiner H. 2007. Delivery of drugs and macromolecules to mitochondria. Adv Drug Deliv Rev 59:729–738.
   PubMed Web of Science ®Google Scholar
• Murase Y, Asai T, Katanasaka Y, Sugiyama T, Shimizu K, Maeda N, Oku N. 2010. A novel DDS strategy, ‘dual-targeting’, and its application for antineovascular therapy. Cancer Lett 287:165–171.
   PubMed Web of Science ®Google Scholar
• Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. 2009. Dendrimers: Emerging polymers for drug-delivery systems. Eur J Pharmaceut Sci 38:185–196.
   PubMed Web of Science ®Google Scholar
• Negussie AH, Miller JL, Reddy G, Drake SK, Wood BJ, Dreher MR. 2010. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release 143:265–273.
   PubMed Web of Science ®Google Scholar
• Neidle S, Thurston DE. 2005. Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 5:285–296.
   PubMed Web of Science ®Google Scholar
• Ng EW, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. 2006. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123–132.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM. 2007. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm 328:86–94.
   PubMed Web of Science ®Google Scholar
• Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. 2004. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 8:335–353.
   PubMed Web of Science ®Google Scholar
• Nobs L, Buchegger F, Gurny R, Allemann E. 2004. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci 93:1980–1992.
   PubMed Web of Science ®Google Scholar
• Norberto SE, Kakar SS. 2009. The use of nanoparticles in LHRH receptor targeted therapy for cancer. Exp Mol Pathol.
   Google Scholar
• Ong W, Yang Y, Cruciano AC, McCarley RL. 2008. Redox-triggered contents release from liposomes. J Am Chem Soc 130:14739–14744.
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. 2002. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172–1181.
   PubMed Web of Science ®Google Scholar
• Park KM, Suh K, Jung H, Lee DW, Ahn Y, Kim J, Baek K, Kim K. 2009. Cucurbituril-based nanoparticles: A new efficient vehicle for targeted intracellular delivery of hydrophobic drugs. Chem Commun (Camb):71–73.
   Google Scholar
• Paschke M. 2006. Phage display systems and their applications. Appl Microbiol Biotechnol 70:2–11.
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M. 2003. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63:7400–7409.
   PubMed Web of Science ®Google Scholar
• Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. 2010. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31:358–365.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. 2007. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760.
   PubMed Web of Science ®Google Scholar
• Peer D, Margalit R. 2004a. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 108:780–789.
   PubMed Web of Science ®Google Scholar
• Peer D, Margalit R. 2004b. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 6:343–353.
   PubMed Web of Science ®Google Scholar
• Phillips JA, Lopez-Colon D, Zhu Z, Xu Y, Tan W. 2008. Applications of aptamers in cancer cell biology. Anal Chim Acta 621:101–108.
   PubMed Web of Science ®Google Scholar
• Piddock LJV. 2006. Multidrug-resistance efflux pumps – not just for resistance. Nature Rev Microbiol 4:629–636.
   PubMed Web of Science ®Google Scholar
• Qian ZM, Li H, Sun H, Ho K. 2002. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54:561–587.
   PubMed Web of Science ®Google Scholar
• Rajendran L, Knolker HJ, Simons K. 2010. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov 9:29–42.
   PubMed Web of Science ®Google Scholar
• Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. 2009. Nanomedicine – challenge and perspectives. Angewandte Chemie-Int Ed 48:872–897.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. 2002. Specialization of tumour vasculature. Nat Rev Cancer 2:83–90.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E, Bhatia SN, Sailor MJ. 2010. Targeting of drugs and nanoparticles to tumors. J Cell Biol 22(188):759–768.
   Google Scholar
• Sapra P, Allen TM. 2003. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 42:439–462.
   PubMed Web of Science ®Google Scholar
• Saul JM, Annapragada AV, Bellamkonda RV. 2006. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 114:277–287.
   PubMed Web of Science ®Google Scholar
• Sawant RM, Cohen MB, Torchilin VP, Rokhlin OW. 2008. Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro. J Drug Targeting 16:601–604.
   PubMed Web of Science ®Google Scholar
• Sawyers C. 2004. Targeted cancer therapy. Nature 432:294–297.
   PubMed Web of Science ®Google Scholar
• Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ. 2002. Hepatic drug targeting: Phase I. Evaluation of polymer bound doxorubicin. J Clin Oncol 20:1668–1676.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Goldenberg DM. 2006. Targeted therapy of cancer: New prospects for antibodies and immunoconjugates. CA Cancer J Clin 56:226–243.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Goldenberg DM. 2008. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev 60:1407–1420.
   PubMed Web of Science ®Google Scholar
• Shi M, Ho K, Keating A, Shoichet MS. 2009a. Doxorubicin-conjugated lmmuno-nanoparticles for intracellular anticancer drug delivery. Adv Functio Mater 19:1689–1696.
   Web of Science ®Google Scholar
• Shi M, Lu J, Shoichet MS. 2009b. Organic nanoscale drug carriers coupled with ligands for targeted drug delivery in cancer. J Mater Chem 19:5485–5498.
   Web of Science ®Google Scholar
• Silverman J, Liu Q, Bakker A, To W, Duguay A, Alba BM, Smith R, Rivas A, Li P, Le H, Whitehorn E, Moore KW, Swimmer C, Perlroth V, Vogt M, Kolkman J, Stemmer WP. 2005. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23:1556–1561.
   PubMed Web of Science ®Google Scholar
• Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. 1998. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 4:623–626.
   PubMed Web of Science ®Google Scholar
• Soussan E, Cassel S, Blanzat M, Rico-Lattes I. 2009. Drug delivery by soft matter: Matrix and vesicular carriers. Angew Chem Int Ed Engl 48:274–288.
   PubMed Web of Science ®Google Scholar
• Sugahara K, Teesalu T, Karmali P, Kotamraju V, Agemy L, Greenwald D, Ruoslahti E. 2010. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328:1031–1035.
   PubMed Web of Science ®Google Scholar
• Sundaram S, Durairaj C, Kadam R, Kompella UB. 2009. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther 8:1655–1665.
   PubMed Web of Science ®Google Scholar
• Thaxton CS, Daniel WL, Giljohann DA, Thomas AD, Mirkin CA. 2009. Templated spherical high density lipoprotein nanoparticles. J Am Chem Soc 131:1384–1385.
   PubMed Web of Science ®Google Scholar
• Tkachenko AG, Xie H, Coleman D, Glomm W, Ryan J, Anderson MF, Franzen S, Feldheim DL. 2003. Multifunctional gold nanoparticle-peptide complexes for nuclear targeting. J Am Chem Soc 125:4700–4701.
   PubMed Web of Science ®Google Scholar
• Toma A, Otsuji E, Kuriu Y, Okamoto K, Ichikawa D, Hagiwara A, Ito H, Nishimura T, Yamagishi H. 2005. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma. Br J Cancer 93:131–136.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. 2009. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 71:431–444.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. 2005a. Lipid-core micelles for targeted drug delivery. Curr Drug Deliv 2:319–327.
   PubMedGoogle Scholar
• Torchilin VP. 2005b. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–160.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. 2006a. Multifunctional nanocarriers. Adv Drug Deliv Rev 58:1532–1555.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. 2006b. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 8:343–375.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. 2007. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. Aaps J 9:E128–147.
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. 2003. Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs. Proc Nat Acad Sci USA 100:6039–6044.
   PubMed Web of Science ®Google Scholar
• Veiseh O, Gunn JW, Zhang M. 2010. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev 62:284–304.
   PubMed Web of Science ®Google Scholar
• Vives E, Schmidt J, Pelegrin A. 2008. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 1786:126–138.
   PubMed Web of Science ®Google Scholar
• Voinea M, Manduteanu I, Dragomir E, Capraru M, Simionescu M. 2005. Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells – a potential tool for specific drug delivery. Pharm Res 22:1906–1917.
   PubMed Web of Science ®Google Scholar
• Wagner S, Rothweiler F, Anhorn MG, Sauer D, Riemann I, Weiss EC, Katsen-Globa A, Michaelis M, Cinatl J Jr, Schwartz D, Kreuter J, von Briesen H, Langer K. 2010. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 31:2388–2398.
   PubMed Web of Science ®Google Scholar
• Wagner V, Dullaart A, Bock AK, Zweck A. 2006. The emerging nanomedicine landscape. Nat Biotechnol 24:1211–1217.
   PubMed Web of Science ®Google Scholar
• Weissig V, Lasch J, Erdos G, Meyer HW, Rowe TC, Hughes J. 1998. DQAsomes: A novel potential drug and gene delivery system made from Dequalinium. Pharm Res 15:334–337.
   PubMed Web of Science ®Google Scholar
• Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, Stahl S. 2004. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel 17:455–462.
   PubMed Web of Science ®Google Scholar
• Wu J, Nantz MH, Zern MA. 2002. Targeting hepatocytes for drug and gene delivery: Emerging novel approaches and applications. Front Biosci 7:d717–725.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Akita H, Kamiya H, Kogure K, Yamamoto T, Shinohara Y, Yamashita K, Kobayashi H, Kikuchi H, Harashima H. 2008. MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim Biophys Acta 1778:423–432.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Harashima H. 2008. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev 60:1439–1462.
   PubMed Web of Science ®Google Scholar
• Yan AC, Levy M. 2009. Aptamers and aptamer targeted delivery. RNA Biol 6:316–320.
   PubMed Web of Science ®Google Scholar
• Yang J, Lee CH, Ko HJ, Suh JS, Yoon HG, Lee K, Huh YM, Haam S. 2007. Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed Engl 46:8836–8839.
   PubMed Web of Science ®Google Scholar
• Yousif LF, Stewart KM, Kelley SO. 2009. Targeting mitochondria with organelle-specific compounds: Strategies and applications. Chembiochem 10:1939–1950.
   PubMed Web of Science ®Google Scholar
• Yu B, Zhao X, Lee LJ, Lee RJ. 2009. Targeted delivery systems for oligonucleotide therapeutics. Aaps J 11:195–203.
   PubMed Web of Science ®Google Scholar
• Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. 1995. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55:3752–3756.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Cao W, Jin H, Lovell JF, Yang M, Ding L, Chen J, Corbin I, Luo Q, Zheng G. 2009. Biomimetic nanocarrier for direct cytosolic drug delivery. Angew Chem Int Ed Engl 48:9171–9175.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen J, Ding L, Jin H, Lovell JF, Corbin IR, Cao W, Lo PC, Yang M, Tsao MS, Luo Q, Zheng G.. 2010. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6:430–437.
   PubMed Web of Science ®Google Scholar
• Zhao X, Li H, Lee RJ. 2008. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 5:309–319.
   PubMed Web of Science ®Google Scholar